Vertex Pharmaceuticals Incorpor

VRTX

Precision medicineBiotech & pharmaceuticals

$548.64vs prev close▲+0.59(+0.11%)

$374.1752W Range$555.32

96% from low

+70.69 (+14.81%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.00%

1M -0.09%p

Holding ETFs

1 ETFs

ARKG

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -100.0% · Market value -100.0% · Weight -0.09%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.03.05	SELL	ARKG	1	$460.82	$461
26.03.04	SELL	ARKG	652	$477.89	$311.6K
26.03.03	SELL	ARKG	19,168	$474.27	$9.1M
26.02.27	SELL	ARKG	2,591	$496.83	$1.3M
26.02.25	SELL	ARKG	2,524	$483.05	$1.2M
25.08.12	BUY	ARKG	2,623	$387.77	$1.0M
24.11.06	SELL	ARKG	5,292	$493.64	$2.6M
24.10.25	SELL	ARKG	505	$477.70	$241.2K
24.10.24	SELL	ARKG	5,008	$471.91	$2.4M
24.10.08	SELL	ARKG	566	$458.94	$259.8K
24.10.07	SELL	ARKG	3,553	$448.60	$1.6M
24.09.23	SELL	ARKG	575	$460.00	$264.5K
24.09.12	SELL	ARKG	411	$478.65	$196.7K
24.09.11	SELL	ARKG	2,358	$474.74	$1.1M
24.09.10	SELL	ARKG	2,704	$470.78	$1.3M

03.05SELL

ARKGClose$460.82Est. total$461

03.04SELL

652

ARKGClose$477.89Est. total$311.6K

03.03SELL

19,168

ARKGClose$474.27Est. total$9.1M

02.27SELL

2,591

ARKGClose$496.83Est. total$1.3M

02.25SELL

2,524

ARKGClose$483.05Est. total$1.2M

08.12BUY

2,623

ARKGClose$387.77Est. total$1.0M

11.06SELL

5,292

ARKGClose$493.64Est. total$2.6M

10.25SELL

505

ARKGClose$477.70Est. total$241.2K

10.24SELL

5,008

ARKGClose$471.91Est. total$2.4M

10.08SELL

566

ARKGClose$458.94Est. total$259.8K

10.07SELL

3,553

ARKGClose$448.60Est. total$1.6M

09.23SELL

575

ARKGClose$460.00Est. total$264.5K

09.12SELL

411

ARKGClose$478.65Est. total$196.7K

09.11SELL

2,358

ARKGClose$474.74Est. total$1.1M

09.10SELL

2,704

ARKGClose$470.78Est. total$1.3M

1 / 2

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 1 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Ray DalioBridgewater Associates

Decreased

27,488

Portfolio Weight

0.05%

Est. Value

$12M

vs Prev Quarter

-28% (38K→27K)

Sold · Q4 2025

Cathie WoodARK Invest

Fully Sold

Portfolio Weight

Prev Holdings

Est. Sold Value

$477.89

Holding Period

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Targets

avg.

$560.21

vs Current ▲ +2.2% upside

Current$548.05

Low ~ High$350.00 ~ $672.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Truist Securities

Buy

$565.00

+3.09%

—

Maintain

2026-08-05

Barclays

Overweight

$617.00

+12.58%

—

Maintain

2026-08-05

TD Cowen

Buy

$550.00

+0.36%

—

Maintain

2026-08-04

Cantor Fitzgerald

Overweight

$595.00

+8.57%

—

Maintain

2026-08-04

Canaccord Genuity

Hold

$442.00

-19.35%

—

Maintain

2026-08-04

1 / 4

Avg Target

$560.21

vs Current ▲ +2.2% upside

Buy

28 analysts

Strong Buy 4Buy 18Hold 4Sell 1Strong Sell 1

Low $350.00

Current $548.05

High $672.00

Firm	Position	Target	Upside	Close	Action	Date
Truist Securities	Buy	$565.00	+3.09%	—	Maintain	26.08.05
Barclays	Overweight	$617.00	+12.58%	—	Maintain	26.08.05
TD Cowen	Buy	$550.00	+0.36%	—	Maintain	26.08.04
Cantor Fitzgerald	Overweight	$595.00	+8.57%	—	Maintain	26.08.04
Canaccord Genuity	Hold	$442.00	-19.35%	—	Maintain	26.08.04

1 / 4

Price Information

Previous Close$540.26

Open$545.10

Day Range$540.70 - $555.31

52-Week Range$374.17 - $555.32

1-Year Change40.91%

Trading Volume

Volume1,074,991

Avg Volume (3mo)1,545,498

Valuation

Market Cap138.9B

Book Value$79.92

Shares Outstanding253,460,924

Financials

Revenue (TTM)12.6B

Net Income4.4B

EPS$17.15

EBITDA5.1B

Profitability

P/E Ratio31.96

P/B Ratio6.86

Return on Equity (ROE)23.54%

Return on Assets (ROA)11.93%

Profit Margin35.00%

EV/EBITDA26.08

Beta0.30

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)75.72

Company Overview

Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for serious diseases, primarily cystic fibrosis (CF). Its main products are a suite of CFTR modulators like TRIKAFTA/KAFTRIO, and it is expanding into other areas such as sickle cell disease, kidney disease, and pain management. Vertex holds a leading market position in CF treatments and is actively pursuing a pipeline of innovative therapies.

P/B

6.86

High valuation

ROE

23.5%

High return

Beta

0.30

Low volatility

RSI(14)

75.7

Overbought

AI-generated summary. Not investment advice.

Vertex Pharmaceuticals Incorpor

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks